Discover the latest open access review on “The effects of psychobiotics on the microbiota-gut-brain axis in early-life stress and neuropsychiatric disorders” recently published in Progress in Neuro-Psychopharmacology and Biological Psychiatry.
This review explores the published evidence on probiotics, both in preclinical and in clinical studies. It also highlights the challenges associated with conducting longitudinal studies to answer outstanding theories to better understand the consequences of early-life stress. So far, the studies support the key role psychobiotics play to improve depression-related issues. These specific study findings are helpful to carry on looking for additional health benefits and positive impacts probiotics have. They encourage the scientific community and contribute to a better understanding on the value of the research and the understanding of the mechanism of actions of probiotics.
With over 330 published in vitro, in vivo and clinical research studies and a collaborative network of industry frontrunners, key opinion leaders, and scientific experts, The Rosell® Institute for Microbiome and Probiotics follows in the footsteps of its founders, to extend the limits of the health applications offered by probiotics.
Contact us for a collaboration email@example.com
Read the full open-access review here: Tremblay, A., et al (2020). The effects of psychobiotics on the microbiota-gut-brain axis in early-life stress and neuropsychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 110142.